Endo Begins Shipment of Authorized Generic Version of PROVENTIL HFA Inhalation Aerosol in the US

Endo International (NASDAQ:ENDP) has announced that one of its operating companies, Par Pharmaceutical (Par), has started shipping an authorized generic version of Merck’s (NYSE:MRK) Proventil HFA Inhalation Aerosol.

As quoted in the press release:

Endo’s subsidiary, Endo Procurement Operations Limited, recently entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co., Inc., of Kenilworth, N.J.allowing Par to launch and distribute an authorized generic of the product.

“We are very pleased to add albuterol sulfate to Par’s portfolio and to be able to offer the authorized generic of the product to patients,” said Tony Pera, President of Par Pharmaceutical. “Par has partnered with Merck several times to bring an authorized generic product to market and we are proud to be a reliable, quality supplier.”

PROVENTIL ^® is a registered trademark of Merck Sharp & Dohme Corp.

Click here to read the full press release.